Farmácia/Notícias da Indústria

Revisão sistemática | Recomendações de diretriz de prática clínica para reduzir ou descontinuar o uso de antidepressivos para depressão.

10 Mai, 2022 | 12:23h

Clinical practice guideline recommendations on tapering and discontinuing antidepressants for depression: a systematic review – Therapeutic Advances in Psychopharmacology

Conteúdos relacionados:

Discontinuing antidepressants: Pearls and pitfalls.

Review | Newer generation antidepressants and withdrawal effects: reconsidering the role of antidepressants and helping patients to stop.

RCT: Maintenance vs. discontinuation of antidepressants in patients who felt well enough to discontinue antidepressant therapy.

A method for tapering antipsychotic treatment that may minimize the risk of relapse

Systematic Review: Managing Antidepressant Discontinuation

Randomized controlled trial: preventive cognitive therapy for prevention of depressive recurrence

M-A: Continuation of antidepressants vs. sequential psychological interventions to prevent relapse in depression.

---

Revisão | Tratamento farmacológico da dor persistente em sobreviventes de câncer.

10 Mai, 2022 | 12:21h

Pharmacologic Management of Persistent Pain in Cancer Survivors – Drugs

---

Diretriz de prática clínica com recomendações estratificadas pelo risco | Inibidores de PCSK9 e ezetimibe para redução de eventos cardiovasculares.

6 Mai, 2022 | 17:45h

PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations – The BMJ

Ver também: PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis – The BMJ

Comunicado de imprensa: Experts recommend additional cholesterol lowering drugs for adults at high heart disease risk – British Medical Journal

---

Erros de medicação, incidentes críticos, eventos adversos relacionados a medicamentos e mais: revisão examinando a terminologia relacionada à segurança do paciente sob anestesia.

6 Mai, 2022 | 17:18h

Medication errors, critical incidents, adverse drug events, and more: a review examining patient safety-related terminology in anaesthesia – British Journal of Anaesthesia

---

OMS alerta para cursos medicamentosos mais curtos para tuberculose resistente.

6 Mai, 2022 | 17:07h

WHO calls for shorter drug course for resistant TB – CIDRAP

Comunicação rápida: Key changes to the treatment of drug-resistant tuberculosis – World Health Organization

---

Tratamento bacteriofágico da infecção disseminada cutânea por Mycobacterium chelonae.

6 Mai, 2022 | 16:43h

Bacteriophage treatment of disseminated cutaneous Mycobacterium chelonae infection – Nature Communications

 

Comentário no Twitter (fio – clique para saber mais)

So excited to share our experience using #bacteriophage for treatment of disseminated cutaneous M. chelonae 🦠 infection!

Amazing collaboration with @GHatfull @DedrickRebekah @TJhaveriMD @dsolsMD https://t.co/LUnigdU9xZ

— Jessica Little, MD (@JessicaLittleMD) May 3, 2022

 

---

Revisão | Opioides e risco de quedas em idosos.

6 Mai, 2022 | 16:36h

Opioids and Falls Risk in Older Adults: A Narrative Review – Drugs & Aging

---

Estudo de coorte | Caracterização do risco de danos em idosos a partir do uso de medicamentos para redução da pressão arterial.

6 Mai, 2022 | 16:35h

Characterising older adults’ risk of harm from blood-pressure lowering medications: a sub-analysis from the PRIME study – Age and Ageing

---

Estudo de coorte | Fragilidade do idoso é significativamente associada com danos relacionados à medicação.

6 Mai, 2022 | 16:33h

A multi-centre cohort study on healthcare use due to medication-related harm: the role of frailty and polypharmacy – Age and Ageing

---

Remdesivir e 3 outros medicamentos para pacientes internados com COVID-19: resultados finais do estudo randomizado WHO Solidarity e metanálise atualizada.

4 Mai, 2022 | 14:07h

Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses – The Lancet

Comentário convidado: When and which patients should receive remdesivir? – The Lancet

---